Navigation Links
FDA Approves VYVANSE(TM) (lisdexamfetamine dimesylate), the First and Only Once-Daily Prodrug Stimulant to Treat ADHD in Adults
Date:4/23/2008

may cause sudden death and serious cardiovascular adverse events. These events have also been reported rarely with amphetamine use.

VYVANSE was generally well tolerated in clinical studies. The most common side effects reported in studies of VYVANSE were: children - decreased appetite, difficulty falling asleep, stomachache, and irritability; adult - decreased appetite, difficulty falling asleep, and dry mouth.

Aggression, new abnormal thoughts/behaviors, mania, growth suppression, worsening of motion or verbal tics, and Tourette's syndrome have been associated with use of drugs of this type. Tell the doctor if you or your child has blurred vision while taking VYVANSE.

Shire PLC

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe. Shire believes that a carefully selected portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company's website: http://www.shire.com.

"Safe Harbor" Statement Under the Private Securities Litigation Reform Act of 1995

Statements included herein that are not historical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, Shire's r
'/>"/>

SOURCE Shire PLC
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Maryland Approves Medicaid Reimbursement for ActiPatch(R)
2. Healthcare Coalition Approves Tools to Improve Patient Safety During Transitions of Care
3. Medicare Approves in Home Sleep Apnea Testing
4. 3SBio Inc. Approves Share Repurchase Program
5. Baxters Board of Directors Approves New Share Repurchase Authorization of $2 Billion
6. FDA Approves PRISTIQ(TM) for the Treatment of Adult Patients with Major Depressive Disorder
7. FDA Approves INTELENCE(TM) (etravirine) for HIV Combination Therapy
8. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
9. FDA Approves New Mechanism of Action Labeling for Ranexa(R)
10. FDA Approves Diovan(R) for Treatment of High Blood Pressure in Children
11. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) as the First Medication for Add-On Treatment of Major Depressive Disorder (MDD)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... pet owners drew up their lists of New Year,s resolutions for ... of my furry companion." Nowadays there are pet salons, dog and ... take the little canine or feline darlings along wherever mommy or ... pricey toys at the pet store. But anyone who has ever ...
(Date:1/14/2014)... , Jan. 14, 2014 The largest ... research medicinal plants and therapeutic derivatives thereof has ... professionals, and researchers about the challenges of adulterated ... http://photos.prnewswire.com/prnh/20100430/DC95601LOGO ) The Society for ...
(Date:1/14/2014)... Boston, MA (PRWEB) January 14, 2014 iLab ... Michelle Detwiler as the new Director of Product Strategy. In ... as well as iLab sub-teams to guide in the development ... that iLab provides the maximum possible benefit to the scientific ...
(Date:1/14/2014)... , Jan. 14, 2014  RXi Pharmaceuticals Corporation ... developing and commercializing innovative therapies addressing major unmet ... it received the Notice of Allowance from the ... unique self-delivering RNAi compounds (sd-rxRNA®), for the treatment ...
Breaking Biology Technology:New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3
... N.Y. Jie Lian, assistant professor in the Department ... Institute, has won a prestigious Faculty Early Career Development ... Lian will use the five-year, $500,000 award to further ... in nuclear energy systems. The CAREER Award is given ...
... ("Oxford"), a specialty finance firm that provides senior debt ... a $15 million round of debt financing for NanoString ... to NanoString from both Oxford and Silicon Valley Bank, ... a $2 million revolving line of credit.  Proceeds of ...
... N.J., April 3, 2012 Laureate Biopharmaceutical Services, Inc. ... announced the appointment of James D. Utterback to the ... ) "Jim is an invaluable ... have access to his deep industry knowledge," said Michael ...
Cached Biology Technology:Rensselaer professor Jie Lian receives NSF CAREER Award 2Oxford Finance and Silicon Valley Bank Provide $15 Million Senior Credit Facility to NanoString Technologies 2Oxford Finance and Silicon Valley Bank Provide $15 Million Senior Credit Facility to NanoString Technologies 3Laureate Biopharma Names James D. Utterback to Board of Directors 2
(Date:4/20/2014)... breast and pancreatic cancers also promote drug-resistance and ultimately ... San Diego School of Medicine have discovered a molecule, ... tumors that appears responsible for inducing tumor metastasis by ... , The findings, published in the April 20, 2014 ... point to new therapeutic opportunities for reversing drug resistance ...
(Date:4/20/2014)... -- Using corn crop residue to make ethanol and ... greenhouse gases than gasoline, according to a study published ... , The findings by a University of Nebraska-Lincoln team ... be used to meet federal mandates to ramp up ... stover -- the stalks, leaves and cobs in cornfields ...
(Date:4/18/2014)... while feeding a world population predicted to reach ... approach to conservation that considers human-altered landscapes such ... and the natural habitat that supports it might ... where at least three-quarters of the land surface ... is vulnerable to human-caused impacts such as climate ...
Breaking Biology News(10 mins):Cancer stem cells linked to drug resistance 2Study casts doubt on climate benefit of biofuels from corn residue 2Study casts doubt on climate benefit of biofuels from corn residue 3Stanford researchers rethink 'natural' habitat for wildlife 2Stanford researchers rethink 'natural' habitat for wildlife 3Stanford researchers rethink 'natural' habitat for wildlife 4
... in humans it is detected in approximately 0.5% ... a kidney abnormality known as hydronephrosis. Hydronephrosis arises because ... bladder is impeded. By studying kidney development in mice, ... Children, Toronto, have identified a new cellular mechanism underlying ...
... BOSTON Congenital heart diseases affect approximately one in ... birth defect and the number-one cause of pediatric deaths. ... drug rapamycin can reverse cardiac muscle damage in a mouse ... the first possible medical treatment for this rare condition, but ...
... choices an individual makes about environmental issues are affected ... network. Michigan State University scientists are studying how to ... sustainability science. "Instead of trying to communicate with ... using the structure of social networks to spread information," ...
Cached Biology News:Study shows rapamycin reverses myocardial defects in mouse model of LEOPARD syndrome 2Study shows rapamycin reverses myocardial defects in mouse model of LEOPARD syndrome 3Sustainability solutions need the power of networks 2